Galapagos NV (GLPG.BR)
7 Mar 2014
|Market Cap (Mil.):||€487.13|
|Shares Outstanding (Mil.):||29.79|
BRUSSELS, March 7 - Galapagos NV : * Says group revenues EUR160 million (+4% over'12), equal to guidance * Says group net loss EUR8.1 million (2012: EUR5.7 m) * Says guidance for 2014 group revenues of 180 million euros (+12.5% over 2013) * Says FY group revenues comprise research and development revenues of EUR 96.4 million and services revenues of EUR63.2 million * Phase 2B clinical program for GLPG0634 is on track to deliver 12 week topline efficacy, safety data for darwin 1 i
BRUSSELS, March 7 - Galapagos NV : * Says Galapagos receives EUR2 million from osteoarthritis alliance with
BRUSSLES, Feb 3 - Galapagos NV : * Receives 2.3 mln euros IWT grant for fibrosis research
BRUSSELS, Jan 13 - Galapagos NV : * Says Galapagos receives 2.9 million euros IWT grant for cystic fibrosis research * Cash awarded by the Flemish Agency for Innovation by Science and Technology (iwt) for cystic fibrosis (cf) research * Says expects to start the first clinical trial before end 2014 * Goal of this 3-year project is to identify and progress multiple promising CF therapies towards pre-clinical candidates * Corrector pre-clinical candidate expected to be nominated bef
BRUSSELS, Nov 27 - Galapagos NV : * GSK to initiate exploratory Phase 2 study with GSK2586184 in patients with
BRUSSELS, Nov 12 - Belgian biotech group Galapagos said its unit Biofocus signed a 3-year research deal with U.S. firm Biogen Idec to find new treatments for scleroderma.
BRUSSELS, Oct 17 - Belgian biotech company Galapagos said on Thursday that it was set to start clinical trials on a possible treatment for cystic fibrosis at the end of 2014.
BRUSSELS - Belgian biotech firm Galapagos has signed a cooperation deal worth up to $405 million with U.S. company AbbVie to develop a new treatment for cystic fibrosis.
Earnings vs. Estimates
Analyst Research Reports
Galapagos NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.